
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
These continue to be less-than-happy times in certain corners of the pharmaceutical industry. Day by day, bad news accumulates. Even the industry's trade organization, the Pharmaceutical Research and Manufacturers Association (PhRMA), acknowledges that something has to give. Where are the unpleasantness and pressure coming from?
These continue to be less-than-happy times in certain corners of the pharmaceutical industry. Day by day, bad news accumulates. Even the industry's trade organization, the Pharmaceutical Research and Manufacturers Association (PhRMA), acknowledges that something has to give. Where are the unpleasantness and pressure coming from?






